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Background. The pathogenesis of hyperhomocysteinemia in
end-stage renal disease (ESRD) is unclear. Folic acid lowers,
but does not normalize, the plasma homocysteine level in pa-
tients with ESRD, but its effect on whole body metabolism of
homocysteine is unknown.
Methods We studied the effect of 3 weeks of oral treatment
with 5 mg folic acid per day on homocysteine metabolism in six
chronic hemodialysis patients and six healthy controls. Primed,
continuous infusions with [2H3-methyl-1-13C] methionine were
used to determine flux rates of methionine transmethylation,
homocysteine remethylation, and homocysteine transsulfura-
tion. Metabolic homocysteine clearance was defined as the ratio
of transsulfuration and plasma homocysteine level.
Results. Folic acid treatment lowered plasma homocysteine
significantly by 39% (95% CI 5 to 73) in the ESRD group, but
plasma homocysteine remained higher than baseline values in
the control group. In ESRD patients, homocysteine remethyla-
tion and methionine transmethylation rate increased by 34%
(95% CI 5 to 62) and 22% (95% CI 5 to 39), respectively
(i.e., levels that were similar to the baseline values of the con-
trol group). Transsulfuration rate and metabolic homocysteine
clearance were not significantly altered by folic acid treatment
in both the ESRD and the control group.
Conclusion. In ESRD patients, folic acid treatment lowers,
but does not normalize plasma homocysteine, whereas homo-
cysteine remethylation and methionine transmethylation in-
crease to levels found in untreated healthy controls. These
findings indicate a persistent, folate-independent, defect in
metabolic homocysteine clearance in ESRD.
Hyperhomocysteinemia is associated with cardiovas-
cular disease [1], and is a prevalent risk factor for car-
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diovascular disease in patients with chronic renal insuf-
ficiency [2]. Hyperhomocysteinemia occurs in 85% to
100% of patients with end-stage renal disease (ESRD)
[3]. The pathophysiologic explanation for the strong in-
verse relationship between renal function and plasma ho-
mocysteine level is controversial and focuses on whether
the defect in homocysteine clearance is located in the
kidneys themselves or should be sought extrarenally [4,
5]. We have studied whole body metabolism of homocys-
teine in patients with ESRD by applying stable isotope
methods [6]. In this model, primed, continuous infusions
with bilabeled methionine were used to determine flux
rates of methionine transmethylation to homocysteine,
homocysteine remethylation to methionine and homo-
cysteine transsulfuration to cysteine (Fig. 1). We found
that transmethylation and remethylation were reduced
in hyperhomocysteinemic ESRD patients compared to
healthy individuals. Transsulfuration was similar, reflect-
ing the same protein (methionine) intake in both groups.
The metabolic clearance of homocysteine by transsulfu-
ration, which is expressed by the ratio of transsulfura-
tion and plasma homocysteine [7], however, was severely
impaired in ESRD patients when compared to healthy
individuals [8].
Several homocysteine-lowering treatments have been
tested in ESRD patients [9]. There is consensus that folic
acid is the cornerstone of any homocysteine-lowering reg-
imen in this patient group; the lowest effective dose seems
to be around 1 mg daily. However, studies on treatment
with folic acid in dialysis patients have shown that normal-
ization of plasma homocysteine is seldom reached, which
has led some authors to suggest that this folic acid resis-
tance is the result of an altered folate metabolism in renal
failure [10]. These claims have so far not been sustained
by studies using active folate compounds instead of folic
acid or intravenous administration of folinic acid [11–13].
In addition, it is not clear from these studies whether folic
acid in ESRD patients is capable of restoring whole body
homocysteine metabolism to normal values.
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Fig. 1. Schematic overview of the homocys-
teine metabolism. Abbreviations are: THF,
tetrahydrofolate; MTHFr, 5,10-methylene-
tetrahydrofolate reductase.
In this study, we aimed to elucidate the apparent folate
resistance in ESRD by investigating the effect of folic
acid administration on plasma homocysteine and whole
body methionine and homocysteine conversion rates in
ESRD patients using the tracer infusion technique with
doubly labeled methionine.
METHODS
Six hemodialysis patients and six healthy control in-
dividuals were studied. Renal diagnoses were chronic
glomerulonephritis in two, polycystic disease in two,
hypertensive renovascular disease in one, and focal
glomerulosclerosis in one. All patients had been on
chronic standard bicarbonate hemodialysis thrice weekly
for at least 6 months. They received one multivita-
min tablet per day containing 2 mg vitamin B6, but no
folic acid or vitamin B12. Table 1 shows other baseline
characteristics.
The study protocol was approved by the ethics com-
mittee of the VU University Medical Center, and all par-
ticipants gave their written informed consent.
Experimental protocol
The study protocol has been described in detail else-
where [6]. Briefly, the participants were kept on a stable
protein diet of 1.0 g/kg/day. In the hemodialysis pa-
tients, the experiments were executed the day between
two regular mid-week dialysis sessions. All individuals
remained fasting and recumbent during the test. Af-
ter baseline samples were taken, a priming bolus of
5.9 lmol NaH13CO3 (99% [13C]) (ARC Laboratories,
Apeldoorn, The Netherlands) was administered, fol-
lowed by a primed (3.5 lmol/kg) constant infusion of
L-[2H3-methyl-1-13C] methionine (95% doubly labeled)
(99% [1-13C]; 99% [2H1]) (Isotec, Miamisburg, OH,
USA) at a rate of 2.2 lmol/kg/hour for 6 hours (5 hours
in control individuals). Plateau enrichment levels were
calculated as the mean of the final five 20-minute in-
Table 1. Baseline characteristics in six patients with end-stage renal
disease (ESRD and six healthy controls
Characteristic Control ESRD
Gender male/female 3/3 3/3
Age years 50 ± 9 49 ± 17
Time on dialysis months 22 ± 9
Body weight kg 76 ± 21 76 ± 19
Fat-free mass kg 62 ± 19 59 ± 12
Homocysteine lmol/L 8.1 ± 1.4 38.7 ± 14.8a
Folate nmol/L 15 (10–18) 18 (14–28)
Vitamin B6 nmol/L 24 (8–58) 21 (11–53)
Vitamin B12 pmol/L 290 (218–332) 293 (182–464)
Values are presented as mean ± SD for variables with a normal distribution
or median (range) for variables with a skewed distribution.
aP < 0.01.
terval samples of the infusion period. Body weight was
measured on a balance scale (accuracy 50 g), and four
skin folds were measured using a caliper (Holtain) (accu-
racy 0.1 mm). Fat-free mass was calculated from skin-fold
measurements according to Durnin and Womerslay [14].
Measurement of skin-fold thicknesses has shown to be a
reliable method to quantify body composition in healthy
individuals and ESRD patients [15].
Intervention
The study protocol was repeated after 3 weeks of oral
treatment with 5 mg folic acid once a day.
Laboratory analyses
Plasma total (free plus protein bound) homocysteine
was measured with the use of a microparticle enzyme im-
munoassay method based on fluorescence polarization
(IMX analyzer) (Abbott, Chicago, IL, USA). Serum fo-
late and vitamin B12 concentrations were measured by
radioassay (ICN, Costa Mesa, CA, USA), and serum vi-
tamin B6 with the use of fluorescence high-performance
liquid chromatography (HPLC) [16]. The methionine
concentration in the infusate was measured with an amino
acid analyzer equipped with a high pressure analytic
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column packed with Utrapac 8 resin (Pharmacia Biotech,
Cambridge, UK). Isotopic enrichments of methionine
in plasma was measured in the acetyl-3,5-bis(trifluoro-
methyl)benzyl derivative with the use of gas chromatog-
raphy mass spectrometry (GCMS), as previously de-
scribed [17]. Enrichments [in mole percent enrichment
(MPE)] were calculated on the basis of the abundance
relative of the (m + 0), (m + 1), and (m + 4) methionine
species [18], and calibration curves obtained from
weighed amounts of tracer (m + 1 and m + 4) and tracee
methionine were used to correct for minor instrument
variation [17]. The 13C-enrichment of carbon dioxide in
breath samples was measured on a dual-inlet isotope ratio
mass spectrometer (VG OPTIMA) (Fisons Instruments,
Middlewich, Cheshire, UK) and expressed in atom per-
cent excess (APE) (%).
Calculations
Doubly labeled methionine (L-[2H3-methyl-1-
13C]methionine) was used as a tracer, according to the
method described by Storch et al [18]. This stable isotope
has a molecular weight of m + 4 relative to natural
methionine (m). The 2H3-methyl label is removed from
methionine during transmethylation and thus 2H3-
methyl-1-13C]methionine is converted to [1-13C] homo-
cysteine. Remethylation will result in the generation of
m + 1 methionine, because the 13C atom of the carboxyl
moiety of homocysteine remains intact. In contrast,
during transsulfuration the carboxyl moiety of [1-13C]
homocysteine loses its 13C atom. When a-ketobutyrate
is oxidized in the Krebs cycle, the label ultimately
appears as 13CO2 in breath air. The m + 4 methionine
tracer is diluted by methionine entering the pool via
the diet, from homocysteine remethylation, and by
free methionine entering from protein breakdown in
the tissues. In steady state, the rate of appearance of
methionine from these sources equals the rate of disap-
pearance (i.e., protein synthesis and transmethylation).
In this model, it is assumed that the intracellular and
intravascular compartments are in rapid and complete
isotopic equilibrium.
From the enrichments of methionine (m + 4 and m +
1), the whole body methionine-methyl rate of appearance
and disappearance (Qm) and methionine-carboxyl rate
of appearance and disappearance (Qc) are calculated as
follows:
Qm = I∗(Etr/E4 − 1)
Qc = I∗(Etr/(E1 + E4) − 1)
in which I is the tracer infusion rate, Etr the enrichment
of the tracer in the infusate, and E1 and E4 are the plasma
plateau enrichments of [m + 1] methionine and [m + 4]
methionine, respectively.
As the rate of appearance equals the rate of disappear-
ance, it follows for Qm:
Qm = appearance = D + B + RM = disappearance
= S + TM
and for Qc:
Qc = appearance = D + B = disappearance = S + TS
in which D is methionine intake via the diet (which is
zero during the infusion), B is methionine release from
protein breakdown, RM is homocysteine remethylation,
S is methionine incorporation in protein synthesis, TM
is methionine transmethylation, and TS is homocysteine
transsulfuration. It follows that:
RM = Qm − Qc.
Transsulfuration rate is calculated from 13CO2 excre-
tion in breath air as follows:
TS= V13CO2∗(1/[13C] methionine enrichment in plasma
−1/[13C] methionine enrichment in tracer infusate)
As methionine is the only precursor of homocysteine,
homocysteine disappearance (RM + TS) equals homo-
cysteine appearance (TM); thus:
TM = RM + TS
The flux rates for transmethylation, remethylation,
and transsulfuration were expressed in lmol/kg fat-free
mass/hour. Metabolic homocysteine clearance was calcu-
lated with the formula: TS/plasma homocysteine level,
and expressed in L/kg fat-free mass/hour.
Statistical methods
Values are expressed as mean ± standard deviation
(SD) or as median with range if data were skewed. Dif-
ferences between mean values before and after treatment
within groups were tested with the paired t test. For com-
parisons between groups, the independent t test was used.
A P value < 0.05 was considered to reflect statistical
significance.
RESULTS
All individuals completed the study protocol.
Baseline plasma homocysteine level was significantly
elevated in the dialysis patients. Before treatment,
remethylation, transmethylation, and transssulfuration
rates were not significantly different between ESRD
and control individuals, whereas metabolic homocys-
teine clearance was significantly lower in ESRD patients
(0.09 ± 0.05 vs. 0.41 ± 0.14 L/kg fat-free mass/hour) (P <
0.01).
After treatment, plasma folate concentration increased
in all participants. Plasma homocysteine concentration
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Table 2. Plasma homocysteine concentrations, one carbon flux rates, and metabolic homocysteine clearance before and after folic acid treatment
in six patients with end-stage renal disease (ESRD) and six healthy controls
ESRD Control
Characteristic Baseline After folic acid Baseline After folic acid
Plasma homocysteine lmol/L 38.7 ± 14.8 20.2 ± 4.1a 8.1 ± 1.4 6.5 ± 1.0c
Remethylation lmol/kg fat-free mass/hour 3.9 ± 1.4 5.1 ± 2.1a 5.0 ± 1.7 6.7 ± 1.1
Transmethylation lmol/kg fat-free mass/hour 6.7 ± 1.7 8.0 ± 1.9b 8.1 ± 1.7 9.0 ± 1.8
Transsulfuration lmol/kg fat-free mass/hour 2.8 ± 0.7 2.9 ± 1.0 3.2 ± 0.9 2.7 ± 1.1
Metabolic homocysteine clearance L/kg fat-free mass/hour 0.09 ± 0.05 0.15 ± 0.05 0.41 ± 0.14 0.43 ± 0.18
Values are mean ± SD.
aP < 0.05; bP < 0.01; and cP = 0.055 compared to baseline.
decreased by 39% (95% CI 5 to 73) in the dialysis pa-
tients and by 18% (95% CI 1 to 35) in the control group
(Table 2). After folic acid treatment, plasma homocys-
teine concentration was still significantly higher in the
dialysis patients compared to the baseline concentration
in the control group. In the dialysis patients, there was a
significant increase in both the remethylation and trans-
methylation rate (Table 2). Remethylation increased by
34% (95% CI 5 to 62) and transmethylation by 22% (95%
CI 5 to 39). In the control group, remethylation and trans-
methylation increased non-significantly by 48% (95%
CI −5 to 102) and by 11% (95% CI −4 to 26), respec-
tively. In both groups, transsulfuration rate and metabolic
homocysteine clearance were not significantly altered by
folic acid treatment (Table 2). Figure 2 shows the effect
of folic acid on remethylation and transmethylation in
dialysis patients and control subjects. The remethylation
and transmethylation rates after folic acid treatment in
the dialysis patients were similar to the baseline levels in
the control individuals (both P = 0.91).
DISCUSSION
The main findings of this study are that oral treatment
with folic acid in ESRD patients (1) lowers, but does
not normalize plasma homocysteine concentration, (2)
increases whole body homocysteine remethylation and
methionine transmethylation rate to normal values, and
(3) does not significantly affect transsulfuration rate.
At first glance, one would expect that the net effect
of an increase in both remethylation and transmethy-
lation is an unchanged plasma homocysteine level, as
the increase in homocysteine removal by remethylation
is offset by a similar increase in homocysteine produc-
tion through transmethylation of methionine. This would
leave the decrease in plasma homocysteine unexplained.
One possible explanation is that transmethylation is not
directly determined in the stable isotope model we used,
but calculated as the sum of remethylation and transsul-
furation. In steady state, any change in remethylation
would be paralleled by the same change in transmethy-
lation if transsulfuration is unchanged, as in our study.
One important condition that must be met before this
calculation can be applied is the presence of a steady
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Fig. 2. Individual changes in remethylation and transmethylation rate
in end-stage renal disease (ESRD) patients and control subjects be-
fore and after treatment with folic acid (5 mg/day). Means with SD are
depicted as bars.
state. From earlier studies, we have established that, after
2 weeks of folic acid treatment in hemodialysis patients,
plasma homocysteine levels are stable [19]. Because the
participants were prescribed a fixed dietary protein (me-
thionine) intake, steady-state conditions were likely to be
present in our study. However, it is possible that in the
initial phase of the folic acid treatment, some of the ho-
mocysteine remethylates to methionine without increas-
ing transmethylation (possibly by intracellular storage
and/or insertion in proteins). After reaching saturation
of this process, plasma homocysteine does not decrease
Stam et al: Effect of folic acid on homocysteine metabolism in ESRD 263
further, because increased remethylation is now balanced
by an increase in transmethylation.
Another explanation may be that folic acid not
only stimulates remethylation, but also improves
the metabolic homocysteine clearance. An improved
metabolic homocysteine clearance would allow the daily
methionine disposal by transsulfuration to take place at a
lower plasma homocysteine concentration. In our study,
there was an increase in metabolic homocysteine clear-
ance which, however, was not significant, but this could
have been due to a type 2 error. Folic acid is not known
to have a direct effect on transsulfuration from single en-
zyme kinetics, but the increase in remethylation could in-
crease levels of methionine and its adenosylated product
S-adenosylmethionine. S-adenosylmethionine is a stim-
ulator of b-cystathionine synthase, the rate limiting en-
zyme of transsulfuration [20].
Our findings may help to explain the cause of hy-
perhomocysteinemia in ESRD patients. From our pilot
study, we have suggested a major role of impaired ho-
mocysteine remethylation in the development of hyper-
homocysteinemia in chronic renal failure [5]. Although
in the present study, baseline remethylation and trans-
methylation rates in the dialysis patients were not signif-
icantly different from controls (possibly a type 2 error),
we have demonstrated differences in remethylation rates
in a larger study [8]. The present study shows that the
remethylation rates in dialysis patients on 5 mg folic acid
per day are virtually the same as in comparable healthy
subjects not on folic acid, whereas plasma homocysteine
levels are still elevated. Therefore, hyperhomocysteine-
mia in ESRD patients can only be partially explained
by a decreased total body remethylation. Another fac-
tor that may play a role is the metabolic homocysteine
clearance, which is decreased by ∼80% in ESRD [8]. For
normalization of plasma homocysteine, restoration of ho-
mocysteine clearance (by transsulfuration) seems to be
required. Stimulation of the transsulfuration in ESRD
patients with vitamin B6 has been disappointing as it did
not result in a significant decrease of fasting plasma ho-
mocysteine [21]. Vitamin B6 seems to have some effect
on plasma homocysteine in renal patients only when the
transsulfuration pathway is further stressed by methio-
nine loading [22]. Interestingly, we have shown earlier
that folic acid is also capable of lowering plasma homo-
cysteine after methionine loading [23] and in the present
study, we observed an increase, although not significant,
in homocysteine clearance. Together, these observations
suggest that folic acid may have a direct or indirect effect
on homocysteine transsulfuration; nevertheless, such an
effect, even if it exists, is clearly insufficient to normalize
plasma homocysteine. Methods that further improve ho-
mocysteine clearance by transsulfuration (or by increased
extraction during dialysis) are probably necessary to nor-
malize plasma homocysteine in ESRD patients.
Folic acid treatment in ESRD patients was paralleled
by an increase in methionine transmethylation in our
study. Transmethylation of methionine provides methyl
groups to the majority of methyl group acceptors in the
body, such as DNA. Recently, Ingrosso et al [24] have
shown that DNA in leukocytes of ESRD patients is hy-
pomethylated and that this could be restored by folate
treatment. The authors suggested that this effect is medi-
ated by an improved transmethylation. The present study
shows that folic acid is indeed capable of increasing trans-
methylation flux in dialysis patients. We conclude that
folic acid treatment in ESRD patients results in an in-
crease of homocysteine remethylation and methionine
transmethylation rate to normal levels and an unaltered
transsulfuration rate. These changes in fluxes are accom-
panied by a lower, but still elevated plasma homocysteine
concentration. Studies aimed at ameloriation of hyperho-
mocysteinemia in ESRD by stimulation of homocysteine
clearance (by transsulfuration) are now warranted.
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